BioWorld20h
2024 Physics Nobel goes for foundations of AI
It’s hard to know where to start in describing the biopharma applications of the 2024 Nobel Prize in Physics. It was awarded ...
BioWorld2h
Chemistry Nobel awarded for 3D protein design, prediction work
David Baker, Demis Hassabis and John Jumper share the 2024 Nobel Prize in Chemistry for their contributions to the science of protein structure. David Baker was awarded half the prize “for ...
BioWorld20h
GE Healthcare participates in €25.3M European theranostics project
GE Healthcare Technologies Inc. is participating in the €25.3 million (US$27.8 million) Thera4care project that aims to ...
BioWorld5h
New CDK12/13 degrader for prostate cancer treatment presented
Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) are involved in the regulation of transcription elongation, DNA damage response and genomic stability balance. A few inhibitors of CDK12- and CDK13 ...
BioWorld1d
Protein design: if you can’t find ’em, make ’em
David Baker, director of the Institute for Protein Design at the University of Washington School of Medicine, is a pioneer in protein design. His contributions have been recognized with countless ...
BioWorld20h
Astrazeneca picks up early stage Lp(a) disruptor in $2B CSPC deal
Astrazeneca plc is adding a preclinical-stage candidate to its cardiovascular pipeline via a potentially $2 billion licensing agreement with CSPC Pharmaceutical Group Ltd., which includes a $100 ...
BioWorld22h
Aviadobio, Astellas ink $2B+ frontotemporal dementia gene therapy deal
Aviadobio Ltd. has entered a potential $2.18 billion license and commercialization agreement for its frontotemporal dementia gene therapy, AVB-101, with Astellas Pharma Inc. Astellas is making a $20 ...
BioWorld1d
Braincheck Assess accurately evaluates cognitive impairment
A digital cognitive assessment developed by Braincheck Inc., Braincheck Assess, proved comparable to the gold-standard ...
BioWorld1d
PKI-179 and MTI-31 identified as potent anti-coronavirus compounds
The COVID-19 pandemic pushed the urgency for effective antiviral drugs against coronaviruses. Researchers from Europe ...
BioWorld1d
Make-or-break adcom next step for Stealth’s Barth syndrome drug
Stealth Biotherapeutics Inc. had hoped the U.S. FDA would have approved its lead candidate, elamipretide, as the first treatment for Barth syndrome by now. Instead, it’s headed to a meet-up with the ...
BioWorld1d
Mestag’s activated fibroblast approach draws Merck in $1.9B deal
Mestag Therapeutics Ltd. has sealed a potential $1.9 billion agreement with Merck & Co. Inc., in which it will apply its expertise in activated fibroblasts to identify novel targets for inflammatory ...
BioWorld1d
Sage stumbles in Alzheimer’s while awaiting Huntington’s data
Bad news has buffeted Sage Therapeutics Inc. twice in the past few months. Now its placebo-controlled phase II Lightwave study of dalzanemdor in Alzheimer's disease has missed the primary outcome ...